<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357498</url>
  </required_header>
  <id_info>
    <org_study_id>14BN151</org_study_id>
    <nct_id>NCT02357498</nct_id>
  </id_info>
  <brief_title>Transsphenoidal Extent of Resection Study</brief_title>
  <acronym>TRANSSPHER</acronym>
  <official_title>Prospective Multicenter Cohort Study Comparing Extent of Tumor Resection Between Microscopic Transsphenoidal Surgery and Fully Endoscopic Transsphenoidal Surgery for Nonfunctioning Pituitary Adenomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Joseph's Hospital and Medical Center, Phoenix</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>John Wayne Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rutgers University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Joseph's Hospital and Medical Center, Phoenix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to compare the extent of resection (EOR) in patients
      with nonfunctioning pituitary adenomas undergoing transsphenoidal surgery using a
      microsurgical technique to those patients who have undergone surgery with a fully endoscopic
      technique. Another goal is to compare surgical complications, endocrine outcomes, visual
      outcomes, length of surgery, length of hospital stay, and readmission rates between the two
      transsphenoidal surgery techniques. This is an observational data collection study with no
      experimental procedures or experimental medicines. Endonasal transsphenoidal removal of a
      pituitary tumor is a unique procedure and there is little information comparing the two
      surgical techniques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of choice for most patients with symptomatic nonfunctioning pituitary adenomas
      is transsphenoidal surgery to improve vision by decompression of the optic chiasm, to prevent
      the development of endocrine dysfunction, and to treat neurological symptoms such as headache
      or cranial neuropathies caused by the tumor. The most widely accepted surgical technique is
      microscopic transsphenoidal surgery, in which an operating microscope is used by the surgeon
      to provide surgical visualization and a nasal speculum is used to maintain the operative
      corridor. [1-4] Recently, fully endoscopic transsphenoidal surgery, in which surgical
      visualization is achieved using an endoscope, has been adopted by many pituitary surgeons
      because the technique offers superior panoramic and angled visualization of the surgical
      target and may permit greater tumor resection. [5-10] There is a vigorous debate in the
      neurosurgical community about the relative merits of the microscopic and endoscopic
      techniques. Proponents of the endoscopic technique argue that the superior visualization
      permits more aggressive tumor resection and better preservation of the normal pituitary
      gland. Proponents of the microscopic technique argue that it permits shorter operative times,
      results in similar surgical outcomes, and has a lower complication rate.

      Despite the adoption of fully endoscopic surgery by many surgeons, no prospective studies
      have compared the extent of tumor resection (EOR) between microscopic and endoscopic
      approaches. Numerous retrospective studies have established the efficacy of each approach,
      but only a few studies present comparative data.[11-13] Recently, McLaughlin et al. noted
      that the addition of endoscopy to microscopic pituitary surgery enhances tumor removal,
      particularly in patients with tumors greater than 20 mm in diameter. [14] This study raises
      the intriguing possibility that certain subgroups of patients (e.g. patients with larger
      tumors) may benefit from endoscopic surgery. In patients with smaller tumors with no
      cavernous sinus invasion, others have shown that the techniques achieve similar EOR. [15]
      That endoscopy may permit more complete tumor resections is a testable hypothesis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients who have complete tumor removal (gross total resection) based on MRI .</measure>
    <time_frame>3 months post surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>volume of residual tumor</measure>
    <time_frame>3 months after date of surgery</time_frame>
    <description>volume, analyzed as a continuous variable; will be determined by manual segmentation using Dominator (www.dominator.com) software under the supervision of a board-certified neuroradiologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of tumor removed</measure>
    <time_frame>3 months post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative cerebral-spinal fluid (CSF) leak</measure>
    <time_frame>6 months (continuous) from surgery</time_frame>
    <description>leakage from nose is a known complication, however, patients who have undergone a second surgery or had a lumbar drain placed to repair the problem will be documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative meningitis</measure>
    <time_frame>6 months (continuous) from surgery</time_frame>
    <description>Determined by symptoms of headache, fever, neck stiffness, nausea and vomiting, and occasionally an altered level of consciousness. CSF culture may be positive for infection and may show elevated glucose and/or protein. CSF may be negative in aseptic meningitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypopituitarism</measure>
    <time_frame>6 months post surgery</time_frame>
    <description>(morning cortisol &lt;4.0ug/dL)(adrenocorticotropic hormone ACTH &lt;6.0pg/mL)(follicular stimulating hormone FSH - mIU/mL. Female: follicular: &lt;3.5; midcycle &lt;4.7; luteal &lt;1.7; postmenopausal &lt;25.8. male &lt;1.7)(luteinizing hormone LH - mIU/mL. Female: follicular &lt;2.4; midcycle &lt;14.0; luteal &lt;1.0; postmenopausal &lt;7.7)(estradiol - pg/mL. female: follicular &lt;13; ovulation &lt;86; luteal &lt;44; postmenopausal &lt;56)(insulin-like growth factor 1 IGF1: 101ng/mL)(testosterone total - ng/dL. Female &lt;6.0; male &lt;270.0)(prolactin ,3.3ng/mL)(thyroid stimulating hormone TSH &lt;.45mU/L)(Thyroxine T4 Free &lt;0.8ng/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diabetes insipidus (DI)</measure>
    <time_frame>6 months post surgery</time_frame>
    <description>to be evaluated by pituitary endocrinologist; serum sodium value is &gt; or equal to 147meq/dl OR if the patient received treatment for DI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual outcomes</measure>
    <time_frame>3 months post surgery</time_frame>
    <description>visual field deficits in this exam will be compared to pre-operative results. Confrontation visual field exam (Donder's test): The examiner will ask the patient to cover one eye and stare at the examiner. The examiner will then move his hand out of the patient's visual field and bring it back in. The examiner will use a slowly wagging finger or a hat pin for this. The patient signals the examiner when his hand comes back into view. Second option is a formal visual field exam (perimetry) performed by a neuro-ophthalmologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypothyroidism</measure>
    <time_frame>6 months post surgery</time_frame>
    <description>(thyroid stimulating hormone TSH &lt;.45mU/L)(thyroxine T4Free &lt;0.8ng/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypogonadism</measure>
    <time_frame>6 months post surgery</time_frame>
    <description>(Testosterone (Total) - ng/dL. Female: &lt; 6.0; Male: &lt; 270.0) (Follicular Stimulating Hormone (FSH) - mIU/mL. Female - Follicular: &lt; 3.5; Midcycle: &lt;4.7; Luteal: &lt; 1.7; Postmenopausal: &lt; 25.8. Male - &lt; 1.5)(Luteinizing Hormone LH - mIU/mL. Female: Follicular: &lt; 2.4; Midcycle: &lt;14.0; Luteal: &lt; 1.0; Postmenopausal: &lt; 7.7. Male: &lt; 1.7)(Estradiol - pg/mL. Female: Follicular: &lt; 13; Ovulation: &lt; 86; Luteal: &lt; 44; Postmenopausal: &lt; 56. Male: &lt; 15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>growth hormone deficiency</measure>
    <time_frame>6 months post surgery</time_frame>
    <description>(insulin tolerance test: growth hormone &lt;3μg/l)(IGF1 &lt;77)(symptoms may include thin and dry skin, low energy, decreased strength and exercise tolerance, decreased muscle mass, weight gain especially around the waist, feelings of anxiety, depression, or sadness causing a change in social behavior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adrenal insufficiency</measure>
    <time_frame>6 months post surgery</time_frame>
    <description>(morning serum cortisol &lt;4.0ug/dL)(ACTH &lt;6.0pg/mL)(sodium &lt;135mEq/L)(abnormal ACTH [cosyntropin] stimulation test)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Pituitary Adenoma</condition>
  <arm_group>
    <arm_group_label>microscopic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Microscopic transsphenoidal surgery, including endoscopic-assisted approach (350 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>endoscopic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fully endoscopic transsphenoidal surgery (350 subjects)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transsphenoidal surgery</intervention_name>
    <arm_group_label>microscopic</arm_group_label>
    <arm_group_label>endoscopic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with suspected nonfunctioning pituitary macroadenomas (≥ 1 cm) with planned
             transsphenoidal surgery

          -  Adults (age 18-80 years)

          -  Medically stable for surgery

          -  Reasonable expectation that patient will complete study and be available for follow-up
             assessments

        Exclusion Criteria:

          -  Prisoners

          -  Pregnant women

          -  Patients with suspected functioning pituitary adenoma

          -  Unable to obtain MRI of the pituitary (e.g., pacemaker, anaphylaxis to gadolinium, low
             GFR)

          -  Pituitary apoplexy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Little, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Joseph's Hospital and Medical Center/Barrow Neurological Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidi Jahnke, RN, MSN</last_name>
    <phone>602-406-6976</phone>
    <email>Heidi.Jahnke@dignityhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barrow Neurological Institute/St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Jahnke, RN, MSN</last_name>
      <phone>602-406-6976</phone>
      <email>Heidi.Jahnke@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Andrew S. Little, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William White, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marvin Bergsneider, MD</last_name>
      <phone>310-206-4100</phone>
    </contact>
    <investigator>
      <last_name>Marvin Bergsneider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Downey</last_name>
      <phone>415-353-7500</phone>
      <email>downeyc@neurosurg.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Manish K Aghi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Heng</last_name>
      <phone>310-315-6125</phone>
      <email>henga@jwci.org</email>
    </contact>
    <investigator>
      <last_name>Daniel F Kelly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Rizio</last_name>
      <phone>312-695-0482</phone>
      <email>nrizio@nmh.org</email>
    </contact>
    <contact_backup>
      <last_name>Sara Thompson</last_name>
      <phone>312-695-0482</phone>
      <email>s-thompson@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James P Chandler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne O'Hara</last_name>
      <phone>617-525-8371</phone>
      <email>johara1@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Sherry Luliano</last_name>
      <phone>617-525-8371</phone>
    </contact_backup>
    <investigator>
      <last_name>Edward R Laws, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Evans, RN</last_name>
      <phone>314-362-3577</phone>
      <email>evansj@wudosis.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Chicoine, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers University Health Services</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James K Liu, MD</last_name>
      <phone>973-972-2323</phone>
    </contact>
    <investigator>
      <last_name>James K Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Colombus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Jelinek</last_name>
      <phone>614-685-1965</phone>
      <email>kathryn.jelinek@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Prevedello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracie Granger, MSHS, BS</last_name>
      <phone>206-320-2800</phone>
      <email>tracie.granger@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Marc R Mayberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johnny Delashaw, MP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wilson CB, Rand RW, Grollmus JM, Heuser G, Levin S, Goldfield E, Schneider V, Linfoot J, Hosobuchi Y. Surgical experience with a microscopic transsphenoidal approach to pituitary tumors and non-neoplastic parasellar conditions. Calif Med. 1972 Nov;117(5):1-9.</citation>
    <PMID>4638402</PMID>
  </reference>
  <reference>
    <citation>Hardy J. Transsphenoidal hypophysectomy. J Neurosurg. 1971 Apr;34(4):582-94.</citation>
    <PMID>5554367</PMID>
  </reference>
  <reference>
    <citation>Fatemi N, Dusick JR, de Paiva Neto MA, Kelly DF. The endonasal microscopic approach for pituitary adenomas and other parasellar tumors: a 10-year experience. Neurosurgery. 2008 Oct;63(4 Suppl 2):244-56; discussion 256. doi: 10.1227/01.NEU.0000327025.03975.BA.</citation>
    <PMID>18981830</PMID>
  </reference>
  <reference>
    <citation>Patel SK, Husain Q, Eloy JA, Couldwell WT, Liu JK. Norman Dott, Gerard Guiot, and Jules Hardy: key players in the resurrection and preservation of transsphenoidal surgery. Neurosurg Focus. 2012 Aug;33(2):E6. doi: 10.3171/2012.6.FOCUS12125.</citation>
    <PMID>22853837</PMID>
  </reference>
  <reference>
    <citation>Dehdashti AR, Ganna A, Karabatsou K, Gentili F. Pure endoscopic endonasal approach for pituitary adenomas: early surgical results in 200 patients and comparison with previous microsurgical series. Neurosurgery. 2008 May;62(5):1006-15; discussion 1015-7. doi: 10.1227/01.neu.0000325862.83961.12.</citation>
    <PMID>18580798</PMID>
  </reference>
  <reference>
    <citation>Gondim JA, Schops M, de Almeida JP, de Albuquerque LA, Gomes E, Ferraz T, Barroso FA. Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center. Pituitary. 2010;13(1):68-77. doi: 10.1007/s11102-009-0195-x. Epub 2009 Aug 21.</citation>
    <PMID>19697135</PMID>
  </reference>
  <reference>
    <citation>Cavallo LM, Prevedello DM, Solari D, Gardner PA, Esposito F, Snyderman CH, Carrau RL, Kassam AB, Cappabianca P. Extended endoscopic endonasal transsphenoidal approach for residual or recurrent craniopharyngiomas. J Neurosurg. 2009 Sep;111(3):578-89. doi: 10.3171/2009.2.JNS081026.</citation>
    <PMID>19326977</PMID>
  </reference>
  <reference>
    <citation>Cavallo LM, Prevedello D, Esposito F, Laws ER Jr, Dusick JR, Messina A, Jane JA Jr, Kelly DF, Cappabianca P. The role of the endoscope in the transsphenoidal management of cystic lesions of the sellar region. Neurosurg Rev. 2008 Jan;31(1):55-64; discussion 64. Epub 2007 Oct 6.</citation>
    <PMID>17922153</PMID>
  </reference>
  <reference>
    <citation>Jho HD, Alfieri A. Endoscopic endonasal pituitary surgery: evolution of surgical technique and equipment in 150 operations. Minim Invasive Neurosurg. 2001 Mar;44(1):1-12.</citation>
    <PMID>11409304</PMID>
  </reference>
  <reference>
    <citation>Jho HD, Carrau RL. Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg. 1997 Jul;87(1):44-51.</citation>
    <PMID>9202264</PMID>
  </reference>
  <reference>
    <citation>Ammirati M, Wei L, Ciric I. Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):843-9. doi: 10.1136/jnnp-2012-303194. Epub 2012 Dec 15. Review.</citation>
    <PMID>23243265</PMID>
  </reference>
  <reference>
    <citation>Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane JA Jr. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab. 2013 Aug;98(8):3190-8. doi: 10.1210/jc.2013-1036. Epub 2013 Jun 4.</citation>
    <PMID>23737543</PMID>
  </reference>
  <reference>
    <citation>McLaughlin N, Eisenberg AA, Cohan P, Chaloner CB, Kelly DF. Value of endoscopy for maximizing tumor removal in endonasal transsphenoidal pituitary adenoma surgery. J Neurosurg. 2013 Mar;118(3):613-20. doi: 10.3171/2012.11.JNS112020. Epub 2012 Dec 14.</citation>
    <PMID>23240699</PMID>
  </reference>
  <reference>
    <citation>Dallapiazza R, Bond AE, Grober Y, Louis RG, Payne SC, Oldfield EH, Jane JA Jr. Retrospective analysis of a concurrent series of microscopic versus endoscopic transsphenoidal surgeries for Knosp Grades 0-2 nonfunctioning pituitary macroadenomas at a single institution. J Neurosurg. 2014 Sep;121(3):511-7. doi: 10.3171/2014.6.JNS131321. Epub 2014 Jul 4.</citation>
    <PMID>24995783</PMID>
  </reference>
  <reference>
    <citation>Little AS, Kelly D, Milligan J, Griffiths C, Rosseau G, Prevedello DM, Carrau R, Jahnke H, Chaloner C, O'Leary J, Chapple K, Nakaji P, White WL. Prospective validation of a patient-reported nasal quality-of-life tool for endonasal skull base surgery: The Anterior Skull Base Nasal Inventory-12. J Neurosurg. 2013 Oct;119(4):1068-74. doi: 10.3171/2013.3.JNS122032. Epub 2013 May 10.</citation>
    <PMID>23662829</PMID>
  </reference>
  <reference>
    <citation>Gao Y, Zhong C, Wang Y, Xu S, Guo Y, Dai C, Zheng Y, Wang Y, Luo Q, Jiang J. Endoscopic versus microscopic transsphenoidal pituitary adenoma surgery: a meta-analysis. World J Surg Oncol. 2014 Apr 11;12:94. doi: 10.1186/1477-7819-12-94.</citation>
    <PMID>24721812</PMID>
  </reference>
  <reference>
    <citation>Goudakos JK, Markou KD, Georgalas C. Endoscopic versus microscopic trans-sphenoidal pituitary surgery: a systematic review and meta-analysis. Clin Otolaryngol. 2011 Jun;36(3):212-20. doi: 10.1111/j.1749-4486.2011.02331.x. Review.</citation>
    <PMID>21752205</PMID>
  </reference>
  <reference>
    <citation>Rudmik L, Starreveld YP, Vandergrift WA, Banglawala SM, Soler ZM. Cost-effectiveness of the endoscopic versus microscopic approach for pituitary adenoma resection. Laryngoscope. 2015 Jan;125(1):16-24. doi: 10.1002/lary.24780. Epub 2014 Jun 17.</citation>
    <PMID>24938934</PMID>
  </reference>
  <reference>
    <citation>Tabaee A, Anand VK, Barrón Y, Hiltzik DH, Brown SM, Kacker A, Mazumdar M, Schwartz TH. Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg. 2009 Sep;111(3):545-54. doi: 10.3171/2007.12.17635. Review.</citation>
    <PMID>19199461</PMID>
  </reference>
  <reference>
    <citation>Zhu M, Yang J, Wang Y, Cao W, Zhu Y, Qiu L, Tao Y, Xu Y, Xu H. [Endoscopic transsphenoidal surgery versus microsurgery for the resection of pituitary adenomas: a systematic review]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014 Mar;49(3):236-9. Review. Chinese.</citation>
    <PMID>24820497</PMID>
  </reference>
  <reference>
    <citation>Komotar RJ, Starke RM, Raper DM, Anand VK, Schwartz TH. Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of craniopharyngiomas. World Neurosurg. 2012 Feb;77(2):329-41. doi: 10.1016/j.wneu.2011.07.011. Epub 2011 Nov 1. Review.</citation>
    <PMID>22501020</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>September 30, 2016</last_update_submitted>
  <last_update_submitted_qc>September 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Joseph's Hospital and Medical Center, Phoenix</investigator_affiliation>
    <investigator_full_name>Madelon Petersen</investigator_full_name>
    <investigator_title>Research clinician</investigator_title>
  </responsible_party>
  <keyword>pituitary</keyword>
  <keyword>adenoma</keyword>
  <keyword>transsphenoidal surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

